{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Anlotinib_Hydrochloride",
  "nciThesaurus": {
    "casRegistry": "1360460-82-7",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "The hydrochloride salt form of anlotinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.",
    "fdaUniiCode": "A3749M6582",
    "identifier": "C106428",
    "preferredName": "Anlotinib Hydrochloride",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C1742",
      "C1967"
    ],
    "synonyms": [
      "1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolyl)oxymethyl)cyclopropanamine, Dihydrochloride",
      "ALTN HCl",
      "Anlotinib Hydrochloride",
      "CATEQUENTINIB DIHYDROCHLORIDE",
      "Cyclopropanamine, 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-, Hydrochloride (1:2)"
    ]
  }
}